MROPF (MicroPort CardioFlow Medtech) Short-term investments

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MROPF MicroPort CardioFlow Medtech Corp MROPF
60 GF Score
Price $0.65
GF Value $3.18
! 11 Warning Signs
View Full Analysis

What is MicroPort CardioFlow Medtech Short-term investments?

Short-term investments only applies to insurance companies.

MROPF
60GF Score
MicroPort CardioFlow Medtech Corp MROPF
Short-term investments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is MicroPort CardioFlow Medtech (MROPF) Overvalued in 2026?

Based on GuruFocus' analysis, MicroPort CardioFlow Medtech stock appears to be undervalued. The current stock price of $0.65 is trading 79.7% below its estimated GF Value™ of $3.18.

Key valuation signals for MROPF:

  • Short-term investments:
  • GF Value™: $3.18 vs. price of $0.65 (79.7% below fair value)
  • GF Score™: 60/100 with 11 warning signs

No single metric tells the full story. See the MROPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


MicroPort CardioFlow Medtech Business Description

Other Exchanges 02160:Hong Kong72X0:Germany
Address No. 501 Niudun Road, Zhangjiang Hi-Tech Park, Pudong New District, Shanghai, CHN, 201203
MicroPort CardioFlow Medtech Corp is a medical device company in China focusing on the research, development, and commercialization of transcatheter and surgical solutions for valvular heart diseases. The company's product portfolio consists of VitaFlow, VitaFlow Liberty, Angelguide and AnchorMan. The Group derives revenue from the sales of medical devices through appointed distributors. It derives maximum revenue from PRC.
60GF Score

Get the complete analysis for MROPF

Short-term investments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.65
Price
$3.18
GF Value